Common heart and blood pressure drugs do not worsen COVID-19 and may actually help

Embargoed until: Publicly released: 2021-04-01 02:00

International

CC-0

UK scientists shave brought together the data from 52 previous studies, including a total of 101,949 COVID-19 patients, to see how the common heart and blood pressure drugs angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) affect outcomes among people with COVID-19. The researchers found no increased risk of worse outcomes for patients on these drugs, and say ACEIs and ARBs may offer protective benefits for patients with COVID-19, particularly those with high blood pressure.

Media release

From: JAMA

Association Between Renin-Angiotensin-Aldosterone System Inhibitors, Clinical Outcomes in Patients With COVID-19

What The Study Did: Researchers compared mortality and severe adverse events in this systematic review and meta-analysis of 52 studies that evaluated clinical outcomes among nearly 102,000 patients with COVID-19 who did and didn’t receive angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs).

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA Network Open

Research:Paper

Organisation/s: Norfolk and Norwich University Hospital, UK

Funder: No information provided.

Media Contact/s

Contact details are only visible to registered journalists.